Lantern Pharma (LTRN) Receivables - Accured (2021 - 2026)

Lantern Pharma (LTRN) has reported Receivables - Accured for 6 consecutive years, with $34000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Accured changed N/A year-over-year to $34000.0; the trailing twelve-month figure through Jun 2026 stood at $34000.0 (changed N/A YoY), and the FY2025 full-year result was $30000.0, down 69.07% from the prior year.
• Receivables - Accured grew to $34000.0 in Q2 2026 per LTRN's latest filing, from $32000.0 in the prior quarter.
• Across five years, Receivables - Accured topped out at $860000.0 in Q4 2023 and bottomed at $30000.0 in Q4 2025.
• Historically, Receivables - Accured has averaged $279666.7 across 5 years, with a median of $228000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Receivables - Accured soared 346.05% in 2022, then tumbled 88.72% in 2024.
• Over 5 years, Receivables - Accured stood at $592000.0 in 2022, then jumped by 45.27% to $860000.0 in 2023, then sank by 88.72% to $97000.0 in 2024, then tumbled by 69.07% to $30000.0 in 2025, then advanced by 13.33% to $34000.0 in 2026.
• According to Business Quant data, Receivables - Accured over the past three periods registered $34000.0, $32000.0, and $30000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.